AA
UTHR icon

Addison Advisors’s United Therapeutics UTHR Stock Holding History

Addison Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-75
Closed -$44.5K – 993
2026
Q1 		$44.5K Hold
75
– – 0.01% 448
2025
Q4 		$36.5K Hold
75
– – 0.01% 464
2025
Q3 		$31.4K Hold
75
– – 0.01% 482
2025
Q2 		$21.6K Hold
75
– – 0.01% 534
2025
Q1 		$23.1K Hold
75
– – 0.01% 486
2024
Q4 		$26.5K Hold
75
– – 0.01% 468
2024
Q3 		$26.9K Hold
75
– – 0.01% 470
2024
Q2 		$23.9K Hold
75
– – 0.01% 464
2024
Q1 		$17.2K Hold
75
– – 0.01% 475
2023
Q4 		$16.5K Hold
75
– – 0.01% 469
2023
Q3 		$16.9K Hold
75
– – 0.01% 437
2023
Q2 		$16.6K Hold
75
– – 0.01% 428
2023
Q1 		$16.8K Hold
75
– – 0.01% 418
2022
Q4 		$20.9K Hold
75
– – 0.01% 374
2022
Q3 		$16K Hold
75
– – 0.01% 384
2022
Q2 		$18K Hold
75
– – 0.01% 372
2022
Q1 		$13K Hold
75
– – 0.01% 450
2021
Q4 		$16K Hold
75
– – 0.01% 368
2021
Q3 		$14K Hold
75
– – 0.01% 287
2021
Q2 		$13K Buy
+75
New +$14.3K 0.01% 287
2020
Q4 		$11K Buy
+75
New +$9.84K 0.01% 287

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Addison Advisors's UTHR Position: Q2 2026 in Review

Addison Advisors sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 75 shares — an estimated $44.5K sold.

Addison Advisors first reported a position in UTHR in Q4 2020 and held it in 21 quarters. The position peaked at $44.5K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Addison Advisors reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Addison Advisors sold 75 United Therapeutics shares in Q2 2026, an estimated $44.5K.
  • Addison Advisors first reported a position in United Therapeutics in Q4 2020 and held it in 21 quarters.
  • Addison Advisors's United Therapeutics position peaked at $44.5K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Addison Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.